Business Context and Reporting Period
Company: Phio Pharmaceuticals Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: March 31, 2020
Event Date: March 31, 2020 (Agreement); April 2, 2020 (Closing)
Context: The Company entered into a Securities Purchase Agreement to raise capital through a public offering of common stock and a concurrent private placement of warrants.
Key Financial Metrics and Transaction Details
- Offering Size: 1,713,064 shares of Common Stock sold at $2.21 per share.
- Private Placement: Warrants issued for 1,713,064 shares (100% of offering shares) at $0.125 per warrant share; exercise price of $2.21 per share.
- Net Proceeds: Approximately $3.5 million after deducting fees and expenses.
- Placement Agent Fees:
- Cash fee: 7.5% of aggregate gross proceeds.
- Management fee: 1.0% of aggregate gross proceeds.
- Non-accountable expenses: $90,000.
- Clearing fees: $12,900.
- Placement Agent Warrants: 128,480 shares (7.5% of offering) with an exercise price of $2.9188, expiring March 31, 2025.
- Warrant Terms: Immediately exercisable (subject to ownership limitations); expire 5.5 years from issuance.
Material Changes
This filing reports a material definitive agreement and unregistered sales of equity securities. The transaction resulted in an immediate increase in outstanding common stock and potential future dilution via warrants. The filing does not provide comparative financial metrics (revenue, profit, cash flow) for the period, as it is a transactional report rather than a periodic financial statement.
Guidance, Outlook, and Risks
Management Commentary: The filing focuses on the execution of the capital raise and does not contain forward-looking guidance on revenue or operational outlook.
Risks and Contingencies:
- Dilution: Issuance of new shares and warrants may dilute existing shareholders.
- Registration Status: Warrants and warrant shares were sold without registration under the Securities Act of 1933, relying on Section 4(a)(2) and Rule 506 exemptions.
- Ownership Limitations: Warrant exercise is subject to certain ownership limitations.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received (reported as approx. $3.5 million).
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and ownership limitations.
- Confirm the impact of the 1,713,064 new shares and 1,713,064 warrant shares on total outstanding share count and earnings per share.
- Assess the valuation impact of the Placement Agent Warrants (128,480 shares) at the higher exercise price of $2.9188.
- Check subsequent filings for any changes in the Company's cash position or use of proceeds.